ONCOSEC MEDICAL Inc: directors' dealings · United States · SEC (Form 4)

About ONCOSEC MEDICAL Inc

OncoSec Medical Incorporated (ticker: ONCS) was a U.S.-based biotechnology company historically listed on NASDAQ in the United States. Its SEC filings and company communications show headquarters locations over time including San Diego, California and later Pennington, New Jersey. OncoSec’s business was built around oncology innovation, specifically intratumoral immunotherapy paired with a proprietary electroporation drug-delivery system. The company traces its biotech operations to March 2011, when it acquired technology and related assets from Inovio Pharmaceuticals, while its corporate predecessor dates back to 2008 under the name Netventory Solutions, Inc. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm)) The company’s core platform was ImmunoPulse® / OMS EP, designed to deliver plasmid DNA directly into solid tumors using electrical pulses. Its lead clinical candidate was TAVO™ (tavokinogene telseplasmid), a DNA-encoded interleukin-12 (IL-12) therapy intended to reshape the immunosuppressive tumor microenvironment and trigger systemic anti-tumor immunity. Historically, OncoSec advanced TAVO both as a monotherapy and in combination with PD-1 inhibitors, including Merck’s KEYTRUDA®, across programs in metastatic melanoma, triple-negative breast cancer, and squamous cell head and neck cancer. The company also explored additional tumor indications and a visceral lesion applicator for deep-seated tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm)) From a competitive standpoint, OncoSec operated in the highly crowded clinical-stage oncology biotechnology segment, where differentiation depends on scientific validation, safety data, and partnership leverage rather than commercial scale. Its investment case historically relied on the novelty of local electroporation-based delivery and the potential for combination therapy with checkpoint inhibitors. OncoSec received important FDA designations in 2017 for TAVO in metastatic melanoma, which supported the development story and underscored the program’s regulatory interest. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm)) Recent company-defining events materially changed the risk profile. SEC filings show Nasdaq non-compliance notices in 2022 and 2023, followed by a voluntary Chapter 7 bankruptcy filing on June 14, 2023, and a subsequent Nasdaq delisting notice. For investors, this is a critical point: ONCS should be viewed as a distressed former NASDAQ-listed biotech in the United States, with severe liquidity, dilution, and going-concern risk rather than as a mature commercial healthcare business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315223005743/form8-k.htm?utm_source=openai))